Interventional Pulmonary Medicine¶
Chapter 310 | Part 7: Disorders of the Respiratory System
KEY CLINICAL POINTS¶
- Interventional pulmonary medicine focuses on minimally invasive therapies for thoracic malignancy, central airway obstruction, pleural disease, and advanced obstructive lung disease.
- Bronchoscopy has evolved with robotic-assisted platforms, electromagnetic navigation, and intraprocedural imaging for improved peripheral lesion diagnosis.
- Central airway obstruction (CAO) is classified as intrinsic, extrinsic, or mixed, with differential diagnoses including malignancy, granulation tissue, and foreign bodies.
- Airway stenting is effective in >90% of CAO cases, with newer biodegradable and drug-coated stents under evaluation.
- Bronchoscopic ablation (e.g., radiofrequency, microwave) is being studied for early-stage lung cancer but lacks long-term survival data compared to SBRT.
1. DEFINITION & OVERVIEW¶
Interventional pulmonary medicine is a subspecialty focusing on diagnostic and therapeutic interventions for airway and pleural disorders. It includes bronchoscopy, endobronchial ultrasound (EBUS), airway stenting, and pleural interventions. The field has advanced with robotic platforms, intraprocedural imaging, and novel stent technologies.
Table 309-3 Predictors of Survival After Lung Transplantation¶
| Donor Factors | Recipient Factors | Donor/Recipient Factors | Posttransplant Factors |
|---|---|---|---|
| HCV donor | Age <70 years | Non–female-to-male transplant | PaOn/FIOn >260 at 72 h |
| Diagnosis other than pulmonary fibrosis, pulmonary hypertension, sarcoidosis, A1AT | On requirement <5 L/min | Higher levels of HLA matching | Fewer hospitalizations for rejection |
| Preserved recipient eGFR | Total bilirubin <2 | Donor/recipient weight ratio >0.7 | Absent need for postoperative ECMO support |
| CI >2 | Avoidance of unplanned conversion to cardiopulmonary bypass | Decreased ischemic time | |
| Higher center volume | Higher center volume |
1.1 Lung Transplantation Management¶
Post-transplant survival rates are lower than other solid-organ transplants, with ~50% experiencing acute rejection within the first year. Chronic lung allograft dysfunction (CLAD) is a major complication, characterized by obliterative bronchiolitis. Immunosuppression regimens balance efficacy with toxicity risks.
1.2 Interventional Techniques¶
Diagnostic bronchoscopy with EBUS and electromagnetic navigation enables peripheral lesion biopsy. Therapeutic interventions include bronchoplasty, stenting, and ablation for airway obstruction. Pleural interventions address effusions and empyema.
2. EPIDEMIOLOGY¶
Lung transplantation has improved survival rates, but long-term outcomes remain suboptimal. CLAD affects ~50% of recipients by 5 years post-transplant. Infection risk persists lifelong, with opportunistic pathogens increasing over time. Central airway obstruction occurs in 10–20% of patients with bronchogenic carcinoma or granulation tissue.
2.1 Risk Factors¶
Donor/recipient mismatch, HCV infection, age >70 years, and poor post-transplant immune suppression increase mortality. In the general population, CAO is more common in smokers and patients with chronic obstructive pulmonary disease (COPD).
3. ETIOLOGY & PATHOPHYSIOLOGY¶
CLAD results from chronic allograft rejection, characterized by obliterative bronchiolitis. Acute rejection involves lymphocytic infiltration, while antibody-mediated rejection features neutrophilic vasculitis. CAO arises from intrinsic tumor growth, extrinsic compression, or mixed etiologies. Pleural effusions result from inflammation, infection, or malignancy.
4. CLINICAL FEATURES¶
Symptoms of CLAD include progressive dyspnea, cough, and reduced exercise tolerance. CAO presents with stridor, dyspnea, and recurrent infections. Pleural effusions cause dyspnea and chest pain. Bronchoscopic ablation for early-stage cancer may improve quality of life but lacks definitive survival data.
4.1 Complications¶
Post-transplant complications include infection, rejection, and CLAD. Airway stenting risks include migration, mucostasis, and granulation tissue. Pleural interventions may lead to infection or pleural thickening.
5. DIFFERENTIAL DIAGNOSIS¶
For CAO, differential diagnoses include malignancy (e.g., bronchogenic carcinoma), granulation tissue, foreign bodies, and idiopathic tracheal stenosis. Pleural effusions require distinction between malignant, tuberculous, and transudative causes.
Table 310-1 Differential Diagnosis of Central Airway Obstruction¶
| MALIGNANT | NONMALIGNANT |
|---|---|
| Primary airway carcinoma | Lymphadenopathy |
| Bronchogenic carcinoma | Sarcoidosis |
| MALIGNANT | NONMALIGNANT |
|---|---|
| Metastatic carcinoma to airway | Granulation tissue from endotracheal tubes |
| Bronchogenic carcinoid | Foreign bodies |
| Carcinoid adenoid cystic | Tracheostomy tubes |
| Mucoepidermoid | Renal cell carcinoma |
| Cartilage and metastatic carcinoma | Breast carcinoma |
| Metastatic carcinoma to airway | Thyroid carcinoma |
| Bronchogenic granulation tissue | Esophageal carcinoma |
| Renal cell carcinoma | Mediastinal tumors |
| Breast carcinoma | Thymus hyperplasia |
| Thyroid carcinoma | Germ cell lymphadenopathy |
| Colon carcinoma | Idiopathic lymphadenopathy |
| Sarcoma | Lymphoma |
| Melanoma | Tuberculosis |
| Laryngeal carcinoma | Amyloid |
| Esophageal carcinoma | Papillomatosis |
| Mediastinal tumors | Granulomatosis with polyangiitis |
5.1 Table 310-1: Differential Diagnosis¶
MALIGNANT: Primary airway carcinoma, metastatic carcinoma, lymphoma. NONMALIGNANT: Lymphadenopathy, sarcoidosis, granulation tissue, foreign bodies.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic bronchoscopy with EBUS and TBNA is gold standard for lung cancer staging. Imaging (CT, MRI) guides endobronchial interventions. Pleural effusions are diagnosed with thoracoscopy or ultrasound-guided biopsy. CLAD is diagnosed via PFT criteria and exclusion of other causes.
6.1 Imaging Techniques¶
Electromagnetic navigation bronchoscopy (ENB) uses CT reconstructions for peripheral lesion targeting. Radial-probe EBUS provides real-time ultrasound guidance for TBNA with 90% sensitivity and 100% specificity.
7. MANAGEMENT & TREATMENT¶
Therapeutic bronchoscopy addresses CAO with balloon bronchoplasty, stenting, or ablation. Pleural effusions are managed with indwelling pleural catheters (IPCs) or decortication. Endobronchial intratumoral chemotherapy (EITC) and photodynamic therapy (PDT) are experimental for early-stage cancer.
7.1 Airway Stenting¶
Stents are effective in >90% of CAO cases. Biodegradable and drug-eluting stents are under evaluation. Complications include migration and granulation tissue formation.
7.2 Pleural Interventions¶
IPCs are as effective as talc pleurodesis for malignant effusions. Intrapleural rtPA and DNase reduce the need for surgery in septic pleural effusions.
8. PROGNOSIS & COMPLICATIONS¶
Lung transplant survival rates are 50–60% at 5 years. CLAD is associated with 50% mortality within 5 years. Airway stenting complications include infection and stent migration. Pleural interventions may lead to pleural thickening or recurrent effusions.
8.1 Long-Term Outcomes¶
Post-transplant patients face risks of hypertension, diabetes, and renal insufficiency. Multidisciplinary care improves long-term outcomes.
9. SPECIAL CONSIDERATIONS¶
Pregnancy requires careful immunosuppression adjustment. Pediatric patients may need smaller bronchoscopes and lower sedation. Elderly patients face higher surgical risks but benefit from minimally invasive approaches.
9.1 Thoracic Ultrasound¶
Ultrasound guides pleural interventions and detects air leaks. It is preferred for real-time guidance in pleuroscopy and catheter placement.
10. KEY POINTS & CLINICAL PEARLS¶
- Bronchoscopy with EBUS is gold standard for lung cancer staging and TBNA. 2. Airway stents are effective for CAO but require careful selection. 3. IPCs are preferred over talc pleurodesis for malignant effusions. 4. Bronchoscopic ablation lacks long-term survival data compared to SBRT. 5. Multidisciplinary care improves outcomes in transplant recipients.